Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio

 Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio

Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio

Shots:

  • Pacira acquires MyoScience, in all stock transaction for $220M. MyoScience to receive $120M upfront and $100M as regulatory and commercial milestones. The transaction is expected to close in Apr’2019
  • The focus of an acquisition is to strengthen Pacira’s footprints in post-surgical analgesics by adding Myoscience’s iovera system to Pacira’s lead candidate Exparel
  • Pacira is planning to change its name to Pacira BioSciences, Inc. to reflect its broad portfolio and expect to complete the acquisition in H2’20

Click here to read full press release/ article | Ref: Pacira | Image: MassDevice

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post